World Health Organization Raises Alert Over Acute Scarcity of Obesity Medications

Less than 10% of patients that would benefit from obesity jabs such as Wegovy can access them, states the World Health Organization as it releases its inaugural advice on the drugs.

With over a billion individuals worldwide now classified as obese, it is urging increased and just access to these injectable treatments.

Per forecasts, in excess of 2,000,000,000 could be obese by 2030 unless action is taken.

"Our latest guidance affirms that obesity is a long-term condition that can be addressed with thorough and continuous support," stated the agency's head Tedros Adhanom Ghebreyesus.

High costs, constrained manufacturing, and logistical bottlenecks are key barriers to widespread availability to the jabs that can help people shift substantial weight, says the agency.

Skinny Jab Supply Crisis

Even under the present most optimistic scenario, the production of GLP-1 therapies might only reach about 100 million people – under 10% of those who need them, according to the health organization.

The recommendation calls on countries and companies to expand access, by strategies like licensing agreements.

A patent on the active ingredient – the core component of the drug Wegovy – is set to lapse in multiple nations in 2026.

How Weight-Loss Injections Work

GLP-1 drugs imitate a body's own hormone to delay gastric emptying, reduce hunger and boost the sense of being full so individuals reduce food intake.

Individuals typically start to lose weight after several weeks of commencing the weekly injections.

Research points to patients may put most of the weight back on after a year of halting the treatment, when their typical appetite return.

Being above a healthy weight increases your likelihood for contracting health problems, such as diabetes, heart disease, stroke, and some malignancies.

Obesity concerns people in all nations and was associated with 3.7 million deaths worldwide in 2024, per the WHO.